Janssen Nearing Application For Japanese Approval Of Razadyne
This article was originally published in PharmAsia News
Janssen Pharmaceutical KK of Japan says its Phase III trial of an Alzheimer's disease drug has moved to the point it plans to apply for marketing approval in Japan next year. Razadyne (galantamine hydrobromide) by Janssen's parent, Johnson & Johnson, already is marketed in more than 50 countries for inhibiting cholinesterase and modulating nicotinic receptors in the brain to promote synthesis of acetylcholine. Razadyne would compete in the Japanese market against Eisai's Aricept (donepezil hydrochloride). (Click here for more - prescription may be required
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.